Partitioning of Time Trends in Prevalence and Mortality of Bladder Cancer in the United States

Overview

Journal Ann Epidemiol

Publisher Elsevier

Specialty Public Health

Date 2020 Jul 28

PMID 32713504

Citations 8

Authors

Igor Akushevich

Arseniy P Yashkin

Brant A Inman

Frank Sloan

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of the study was to evaluate the relative contributions of incidence, stage-specific relative survival, and stage ascertainment to changes in bladder cancer (BC) prevalence and incidence-based mortality.

Methods: Partitioning of prevalence and incidence-based mortality trends into their epidemiologic components.

Results: BC prevalence estimated from our model increased but at monotonically decreasing rates until 2007, after which it decreased again. The main forces underlying observed trends in BC prevalence were relative BC survival, which improved throughout the period, and BC incidence, which increased at a decreasing rate until 2005 and declined thereafter. Mortality of persons ever diagnosed with BC increased at an increasing rate until 1997, increased at a decreasing rate from 1997 to 2005, and decreased thereafter. The primary forces accounting for mortality trends were changes in mortality in the general population, which improved at an increasing rate during most of 1992-2010, the most important factor, and changes in incidence. Stage ascertainment did not improve during 1992-2010.

Conclusions: Although mortality rates improved, these gains largely reflected improvements in U.S. population survival rather than from improvements in BC-specific outcomes.

Citing Articles

Decomposition of Heart Failure Prevalence and Mortality Among Older Adults in the United States: Medicare-Based Partitioning Analysis.

Yu B, Kravchenko J, Yashkin A, Akushevich I JMIR Public Health Surveill. 2024; 10:e51989.

PMID: 39621935 PMC: 11611790. DOI: 10.2196/51989.

Decomposition of disparities in life expectancy with applications to administrative health claims and registry data.

Akushevich I, Yashkin A, Kovtun M, Stallard E, Yashin A, Kravchenko J Theor Popul Biol. 2023; 153:50-68.

PMID: 37295513 PMC: 10526891. DOI: 10.1016/j.tpb.2023.05.001.

Forecasting prevalence and mortality of Alzheimer's disease using the partitioning models.

Akushevich I, Yashkin A, Kovtun M, Kravchenko J, Arbeev K, Yashin A Exp Gerontol. 2023; 174:112133.

PMID: 36842469 PMC: 10103071. DOI: 10.1016/j.exger.2023.112133.

Underlying mechanisms of change in cancer prevalence in older U.S. adults: contributions of incidence, survival, and ascertainment at early stages.

Akushevich I, Yashkin A, Kovtun M, Yashin A, Kravchenko J Cancer Causes Control. 2022; 33(9):1161-1172.

PMID: 35799033 PMC: 9360135. DOI: 10.1007/s10552-022-01595-6.

Epidemiology of geographic disparities in heart failure among US older adults: a Medicare-based analysis.

Yu B, Akushevich I, Yashkin A, Yashin A, Lyerly H, Kravchenko J BMC Public Health. 2022; 22(1):1280.

PMID: 35778761 PMC: 9248157. DOI: 10.1186/s12889-022-13639-2.

References

Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

Crivelli J, Xylinas E, Kluth L, Rieken M, Rink M, Shariat S . Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol. 2013; 65(4):742-54. DOI: 10.1016/j.eururo.2013.06.010. View

Saint-Jacques N, Parker L, Brown P, Dummer T . Arsenic in drinking water and urinary tract cancers: a systematic review of 30 years of epidemiological evidence. Environ Health. 2014; 13:44. PMC: 4088919. DOI: 10.1186/1476-069X-13-44. View

Masic S, Smaldone M . Treatment delays for muscle-invasive bladder cancer. Cancer. 2019; 125(12):1973-1975. DOI: 10.1002/cncr.32047. View

Sloan F, Yashkin A, Akushevich I, Inman B . The Cost to Medicare of Bladder Cancer Care. Eur Urol Oncol. 2019; 3(4):515-522. DOI: 10.1016/j.euo.2019.01.015. View

Cumberbatch M, Rota M, Catto J, La Vecchia C . The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol. 2015; 70(3):458-66. DOI: 10.1016/j.eururo.2015.06.042. View

Akushevich I, Yashkin A, Kravchenko J, Fang F, Arbeev K, Sloan F . Theory of partitioning of disease prevalence and mortality in observational data. Theor Popul Biol. 2017; 114:117-127. PMC: 5459580. DOI: 10.1016/j.tpb.2017.01.003. View

Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P . Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012; 63(2):234-41. DOI: 10.1016/j.eururo.2012.07.033. View

Darling H, Bellmunt J . Immunotherapy in non-metastatic urothelial cancer: back to the 'future'. Expert Opin Biol Ther. 2019; 19(7):685-695. DOI: 10.1080/14712598.2019.1604673. View

10.

Akushevich I, Kravchenko J, Yashkin A, Fang F, Yashin A . Partitioning of time trends in prevalence and mortality of lung cancer. Stat Med. 2019; 38(17):3184-3203. PMC: 8447842. DOI: 10.1002/sim.8170. View

11.

Hankey B, Ries L, Edwards B . The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999; 8(12):1117-21. View

12.

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

13.

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F . Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. View

14.

Akushevich I, Yashkin A, Kravchenko J, Fang F, Arbeev K, Sloan F . Identifying the causes of the changes in the prevalence patterns of diabetes in older U.S. adults: A new trend partitioning approach. J Diabetes Complications. 2018; 32(4):362-367. PMC: 5849520. DOI: 10.1016/j.jdiacomp.2017.12.014. View

15.

Akushevich I, Yashkin A, Kravchenko J, Fang F, Arbeev K, Sloan F . A forecasting model of disease prevalence based on the McKendrick-von Foerster equation. Math Biosci. 2019; 311:31-38. PMC: 6916255. DOI: 10.1016/j.mbs.2018.12.017. View

16.

Warren G, Alberg A, Kraft A, Cummings K . The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care. Cancer. 2014; 120(13):1914-6. PMC: 5928784. DOI: 10.1002/cncr.28695. View

17.

Freedman N, Silverman D, Hollenbeck A, Schatzkin A, Abnet C . Association between smoking and risk of bladder cancer among men and women. JAMA. 2011; 306(7):737-45. PMC: 3441175. DOI: 10.1001/jama.2011.1142. View

18.

Cumberbatch M, Jubber I, Black P, Esperto F, Figueroa J, Kamat A . Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eur Urol. 2018; 74(6):784-795. DOI: 10.1016/j.eururo.2018.09.001. View

19.

Rao A, Patel M . A review of avelumab in locally advanced and metastatic bladder cancer. Ther Adv Urol. 2019; 11:1756287218823485. PMC: 6354303. DOI: 10.1177/1756287218823485. View